{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:28:41Z","timestamp":1769045321503,"version":"3.49.0"},"reference-count":42,"publisher":"BMJ","issue":"10","funder":[{"name":"FDA","award":["RO1FD004147"],"award-info":[{"award-number":["RO1FD004147"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"accepted":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To confirm that levetiracetam (LEV) demonstrates predictable pharmacokinetics(PK) at higher doses and to study the pharmacodynamics(PD) of LEV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Pharmacokinetic data from the NEOLEV1 and NEOLEV2 trials were analysed using a non-linear mixed effects modelling approach. A post hoc analysis of the effect of LEV on seizure burden was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Neonatal intensive care unit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Term neonates with electrographically confirmed seizures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>In NEOLEV1, neonates with seizures persisting following phenobarbital (PHB) received LEV 20 or 40\u2009mg\/kg bolus followed by 5 or 10 mg\/kg maintenance dose(MD) daily. In NEOLEV2, patients received a 40 mg\/kg intravenous LEV load, followed by 10\u2009mg\/kg doses 8 hourly. If seizures persisted, a further 20\u2009mg\/kg intravenous load was given. If seizures persisted, PHB was given. PK data were collected from 16 NEOLEV1 patients and 33 NEOLEV2 patients. cEEG data from 48 NEOLEV2 patients were analysed to investigate onset of action and seizure burden reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Clearance (CL) and volume of distribution (V<jats:sub>d<\/jats:sub>) were determined. Covariates that significantly affected LEV disposition were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Primary outcome: The median initial LEV level was 57 \u00b5g\/mL (range 19\u2013107) after the first loading dose and at least 12 \u00b5g\/mL at 48 hours in all infants. CL and V<jats:sub>d<\/jats:sub>were estimated to be 0.0538 L\/hour and 0.832 L, respectively. A direct relationship between postnatal age and CL was observed. The final population pharmacokinetic(PopPK) model described the observed data well without significant biases. CL and V<jats:sub>d<\/jats:sub>were described as CL (L\/hour)=0.0538\u00d7(weight in kg\/3.34)0.75\u00d7(postnatal age in days\/5.5) 0.402 and V<jats:sub>d<\/jats:sub>(L)=0.832\u00d7(weight in kg\/3.34).<\/jats:p><jats:p>Seizure burden reduced within 30\u2009min of LEV administration. 28% of patients were completely seizure free after LEV. In an additional 25% of patients, seizure burden reduced by 50%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LEV pharmacokinetics remained predictable at higher doses. Very high-dose LEV can now be studied in neonates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01720667\">NCT01720667<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2022-324952","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:20:24Z","timestamp":1718904024000},"page":"854-860","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic and pharmacodynamic data from the NEOLEV1 and NEOLEV2 studies"],"prefix":"10.1136","volume":"109","clinical-trial-number":[{"clinical-trial-number":"nct01720667","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01720667","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05610085","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04519645","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3307","authenticated-orcid":false,"given":"Cynthia","family":"Sharpe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek Z","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail E","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilly","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund V","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"2024110504400716000_109.10.854.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2008.04.008"},{"key":"2024110504400716000_109.10.854.2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00002"},{"key":"2024110504400716000_109.10.854.3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.222550499"},{"key":"2024110504400716000_109.10.854.4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23600"},{"key":"2024110504400716000_109.10.854.5","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1111\/j.1528-1167.2011.03297.x","article-title":"Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain","volume":"52","author":"Forcelli","year":"2011","journal-title":"Epilepsia"},{"key":"2024110504400716000_109.10.854.6","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.188862"},{"key":"2024110504400716000_109.10.854.7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/epi.13365","article-title":"Anticonvulsant drug-induced cell death in the developing white matter of the rodent brain","volume":"57","author":"Kaushal","year":"2016","journal-title":"Epilepsia"},{"key":"2024110504400716000_109.10.854.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.01.006"},{"key":"2024110504400716000_109.10.854.9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.earlhumdev.2012.12.002","article-title":"The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury","volume":"89","author":"Kilicdag","year":"2013","journal-title":"Early Hum Dev"},{"key":"2024110504400716000_109.10.854.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00410-5"},{"key":"2024110504400716000_109.10.854.11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2014.01.034","article-title":"Levetiracetam increases neonatal hypoxic-ischemic brain injury under normothermic, but not hypothermic conditions","volume":"1556","author":"Griesmaier","year":"2014","journal-title":"Brain Res"},{"key":"2024110504400716000_109.10.854.12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2016.05.040","article-title":"Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain","volume":"1646","author":"Strasser","year":"2016","journal-title":"Brain Res"},{"key":"2024110504400716000_109.10.854.13","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.126250"},{"key":"2024110504400716000_109.10.854.14","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13335"},{"key":"2024110504400716000_109.10.854.15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.41300.x"},{"key":"2024110504400716000_109.10.854.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01974.x"},{"key":"2024110504400716000_109.10.854.17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1528-1167.2007.01090.x","article-title":"Pharmacokinetics of levetiracetam in infants and young children with epilepsy","volume":"48","author":"Glauser","year":"2007","journal-title":"Epilepsia"},{"key":"2024110504400716000_109.10.854.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00005.x"},{"key":"2024110504400716000_109.10.854.19","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2012.51"},{"key":"2024110504400716000_109.10.854.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.03.057"},{"key":"2024110504400716000_109.10.854.21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/jcpt.12658","article-title":"Population pharmacokinetics of levetiracetam in neonates with seizures","volume":"43","author":"Lima-Rogel","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2024110504400716000_109.10.854.22","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3182","article-title":"Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial","volume":"145","author":"Sharpe","year":"2020","journal-title":"Pediatrics"},{"key":"2024110504400716000_109.10.854.23","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13215"},{"key":"2024110504400716000_109.10.854.24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1528-1167.2011.03401.x","article-title":"The temporal evolution of electrographic seizure burden in neonatal hypoxic ischemic encephalopathy","volume":"53","author":"Lynch","year":"2012","journal-title":"Epilepsia"},{"key":"2024110504400716000_109.10.854.25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40262-017-0537-1","article-title":"Levetiracetam clinical pharmacokinetic monitoring in pediatric patients with epilepsy","volume":"56","author":"Tan","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2024110504400716000_109.10.854.26","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14671"},{"key":"2024110504400716000_109.10.854.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.06.009"},{"key":"2024110504400716000_109.10.854.28","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1528-1167.2010.02519.x","article-title":"High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy","volume":"51","author":"Depositario-Cabacar","year":"2010","journal-title":"Epilepsia"},{"key":"2024110504400716000_109.10.854.29","unstructured":"A dose escalation study of Levetiracetam in the treatment of neonatal seizures. 2023. Available: https:\/\/ClinicalTrials.gov\/show\/NCT05610085"},{"key":"2024110504400716000_109.10.854.30","unstructured":"A study to evaluate the efficacy, safety, and pharmacokinetics of Lacosamide in neonates with repeated Electroencephalographic neonatal seizures. 2023. Available: https:\/\/ClinicalTrials.gov\/show\/NCT04519645"},{"key":"2024110504400716000_109.10.854.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2010-8","article-title":"Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the eclipse study: study protocol for a randomised controlled trial","volume":"18","author":"Lyttle","year":"2017","journal-title":"Trials"},{"key":"2024110504400716000_109.10.854.32","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-017-0887-8"},{"key":"2024110504400716000_109.10.854.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00104-1"},{"key":"2024110504400716000_109.10.854.34","first-page":"5719","article-title":"Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures","volume":"9","author":"Mumoli","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2024110504400716000_109.10.854.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2009.11.008"},{"key":"2024110504400716000_109.10.854.36","unstructured":"Smith MP . In: Sharpe C , ed. Science director, toxicology. 2023."},{"key":"2024110504400716000_109.10.854.37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.seizure.2020.08.030","article-title":"High-dose levetiracetam for neonatal seizures: a retrospective review","volume":"82","author":"Hnaini","year":"2020","journal-title":"Seizure"},{"key":"2024110504400716000_109.10.854.38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/j.1950-6945.2000.tb00363.x","article-title":"Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles","volume":"2","author":"Genton","year":"2000","journal-title":"Epileptic Disord"},{"key":"2024110504400716000_109.10.854.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827f0874"},{"key":"2024110504400716000_109.10.854.40","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120016959"},{"key":"2024110504400716000_109.10.854.41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2710.2012.01361.x","article-title":"Overdose with levetiracetam: a case report and review of the literature","volume":"38","author":"Larkin","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2024110504400716000_109.10.854.42","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-014-0384-5"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2022-324952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:42:04Z","timestamp":1730810524000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2022-324952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,9,25]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/archdischild-2022-324952"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2022-324952","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}